{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:28:06Z","timestamp":1790803686160,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministry of Health, Labour and Welfare of Japan"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","respiratoryinvestigation.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.resinv.2017.10.004","type":"journal-article","created":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T05:18:55Z","timestamp":1513401535000},"page":"136-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: A historically controlled study"],"prefix":"10.1016","volume":"56","author":[{"given":"Susumu","family":"Sakamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshige","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Isshiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Sugino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakae","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2017.10.004_bib1","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1164\/rccm.200703-463PP","article-title":"Acute exacerbation of idiopathic fibrosis","volume":"176","author":"Collard","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2017.10.004_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute Exacerbation of Idiopathic Pulmonary Fibrosis: an International Working Group Report","volume":"194","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2017.10.004_bib3","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1378\/chest.103.6.1808","article-title":"Acute exacerbation in idiopathic pulmonary fibrosis: analysis of clinical and pathologic findings in three cases","volume":"103","author":"Kondoh","year":"1993","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2017.10.004_bib4","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2017.10.004_bib5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ejim.2007.04.024","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review","volume":"19","author":"Agarwal","year":"2008","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.resinv.2017.10.004_bib6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2169\/internalmedicine.42.565","article-title":"Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid","volume":"42","author":"Inase","year":"2003","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2017.10.004_bib7","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.2169\/internalmedicine.44.1144","article-title":"Cyclosporin treatment in steroid-resistant and acutely exacerbated interstitial pneumonia","volume":"44","author":"Homma","year":"2005","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2017.10.004_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2169\/internalmedicine.49.2359","article-title":"Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis","volume":"49","author":"Sakamoto","year":"2010","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2017.10.004_bib9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2169\/internalmedicine.50.4327","article-title":"Tacrolimus and steroid treatment for acute exacerbation of idiopathic pulmonary fibrosis","volume":"50","author":"Horita","year":"2011","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2017.10.004_bib10","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1183\/09031936.00127311","article-title":"Exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids and cyclophosphamide pulses","volume":"38","author":"Morawiec","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2017.10.004_bib11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2141.2005.05753.x","article-title":"The interactions between inflammation and coagulation","volume":"131","author":"Esmon","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.resinv.2017.10.004_bib12","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1172\/JCI22782","article-title":"The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel anti-inflammatory mechanism","volume":"115","author":"Abeyama","year":"2005","journal-title":"J Clin Investig"},{"key":"10.1016\/j.resinv.2017.10.004_bib13","doi-asserted-by":"crossref","first-page":"L3","DOI":"10.1152\/ajplung.90637.2008","article-title":"Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis","volume":"299","author":"Collard","year":"2010","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.resinv.2017.10.004_bib14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0049-3848(95)00025-9","article-title":"Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis","volume":"77","author":"Kotani","year":"1995","journal-title":"Thromb Res"},{"key":"10.1016\/j.resinv.2017.10.004_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/916486","article-title":"Gradual increase of high mobility group protein b1 in the lungs after the onset of acute exacerbation of idiopathic pulmonary fibrosis","author":"Ebina","year":"2011","journal-title":"Pulm Med"},{"key":"10.1016\/j.resinv.2017.10.004_bib16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000369828","article-title":"Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study","volume":"89","author":"Isshiki","year":"2015","journal-title":"Respiration."},{"key":"10.1016\/j.resinv.2017.10.004_bib17","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1378\/chest.14-2746","article-title":"Recombinant human thrombomodulin in acute exacerbation of idiopathic pulmonary fibrosis","volume":"148","author":"Kataoka","year":"2015","journal-title":"Chest."},{"key":"10.1016\/j.resinv.2017.10.004_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.pupt.2014.04.008","article-title":"Thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis: a proof of concept study","volume":"29","author":"Tsushima","year":"2014","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.resinv.2017.10.004_bib19","first-page":"5755","article-title":"Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study","volume":"23","author":"Abe","year":"2015","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.resinv.2017.10.004_bib20","unstructured":"Japanese Respiratory Society\u2019s Committee formulating diagnosis and treatment guideline for diffuse lung diseases. Clinical diagnostic and treatment guidance for idiopathic interstitial pneumonias. Tokyo, Nankodo; 2011. p. 67\u201373."},{"key":"10.1016\/j.resinv.2017.10.004_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.resinv.2014.08.003","article-title":"The usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment","volume":"53","author":"Homma","year":"2015","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2017.10.004_bib22","doi-asserted-by":"crossref","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","article-title":"A multidimensional index and staging system for idiopathic pulmonary fibrosis","volume":"156","author":"Ley","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.resinv.2017.10.004_bib23","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1164\/rccm.200709-1365OC","article-title":"Computed tomography findings of acute exacerbation of idiopathic pulmonary fibrosis","volume":"178","author":"Akira","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2017.10.004_bib24","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1378\/chest.128.3.1475","article-title":"Anticoagulant therapy for idiopathic pulmonary fibrosis","volume":"128","author":"Kubo","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2017.10.004_bib25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1164\/rccm.201202-0314OC","article-title":"A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis","volume":"186","author":"Noth","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2017.10.004_bib26","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2017.10.004_bib27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0039-6060(99)70182-0","article-title":"Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes","volume":"126","author":"Wang","year":"1999","journal-title":"Surgery"},{"key":"10.1016\/j.resinv.2017.10.004_bib28","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1164\/rccm.200402-188OC","article-title":"Contributions of high mobility group box protein in experimental and clinical acute lung injury","volume":"170","author":"Ueno","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2017.10.004_bib29","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1183\/09031936.00159709","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome","volume":"37","author":"Song","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2017.10.004_bib30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000329891","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors","volume":"83","author":"Blancal","year":"2012","journal-title":"Respiration"},{"key":"10.1016\/j.resinv.2017.10.004_bib31","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1055\/s-0037-1614900","article-title":"The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation \u2013 a comparison with other anticoagulants","volume":"82","author":"Mohri","year":"1999","journal-title":"Thromb Haemost"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534517301491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534517301491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T03:39:17Z","timestamp":1570505957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534517301491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S2212534517301491"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2017.10.004","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: A historically controlled study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2017.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}